Literature DB >> 15390070

Brain parenchyma sonography detects preclinical parkinsonism.

Uwe Walter1, Christine Klein, Ruediger Hilker, Reiner Benecke, Peter P Pramstaller, Dirk Dressler.   

Abstract

Substantia nigra (SN) hyperechogenicity on brain parenchyma sonography (BPS) is highly characteristic for idiopathic PD. We studied 7 symptomatic and 7 asymptomatic parkin mutation carriers (PMC) from a large kindred with adult-onset parkinsonism. BPS revealed larger SN echogenic sizes in PMC with parkin mutations on both alleles (homozygous, compound-heterozygous), compared to PMC with only one mutated allele (Mann-Whitney U test, P = 0.007). In symptomatic PMC, larger SN echogenic size was correlated with younger age at onset of the disease (Spearman rank correlation, Rho = -0.937, P = 0.002) but not with age, disease duration, or disease severity. BPS demonstrated SN hyperechogenicity, in concordance with abnormal nigrostriatal (18)F-dopa positron emission tomography (PET), in all symptomatic and 3 asymptomatic PMC. In 2 asymptomatic PMC, PET and BPS were normal. However, in another 2 asymptomatic PET-normal PMC, SN hyperechogenicity could be detected. Data suggest SN hyperechogenicity as an early marker to detect preclinical parkinsonism. 2004 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15390070     DOI: 10.1002/mds.20232

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  26 in total

Review 1.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.

Authors:  Uwe Walter
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

Review 2.  Early diagnosis of Parkinson's disease.

Authors:  Jörg Spiegel; Alexander Storch; Wolfgang H Jost
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

3.  Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism.

Authors:  Chung-Fen Tsai; Ruey-Meei Wu; Yu-Weng Huang; Li-Ling Chen; Ping-Keung Yip; Jiann-Shing Jeng
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

4.  Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency.

Authors:  Jacqueline Hoeppner; Lara Prudente-Morrissey; Sabine Christiane Herpertz; Reiner Benecke; Uwe Walter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-09-19       Impact factor: 5.270

5.  Substantia nigra hyperechogenicity with LRRK2 G2019S mutations.

Authors:  Norbert Brüggemann; Johann Hagenah; Kaili Stanley; Christine Klein; Cuiling Wang; Deborah Raymond; Laurie Ozelius; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2011-02-10       Impact factor: 10.338

Review 6.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes.

Authors:  Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2011-01-05       Impact factor: 3.575

Review 7.  Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease.

Authors:  Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2010-09-10       Impact factor: 3.575

8.  Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease.

Authors:  M J Barrett; J Hagenah; V Dhawan; S Peng; K Stanley; D Raymond; A Deik; S J Gross; N Schreiber-Agus; A Mirelman; K Marder; L J Ozelius; D Eidelberg; S B Bressman; R Saunders-Pullman
Journal:  Parkinsonism Relat Disord       Date:  2012-10-10       Impact factor: 4.891

Review 9.  Transcranial duplex in the differential diagnosis of parkinsonian syndromes: a systematic review.

Authors:  Annemarie M M Vlaar; Angela Bouwmans; Werner H Mess; Selma C Tromp; Wim E J Weber
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

10.  Prodromal non-motor symptoms of Parkinson's disease.

Authors:  Clelia Pellicano; Dario Benincasa; Vincenzo Pisani; Francesca R Buttarelli; Morena Giovannelli; Francesco E Pontieri
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.